News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
351,168 Results
Type
Article (19900)
Company Profile (124)
Press Release (331144)
Section
Business (112807)
Career Advice (862)
Deals (20248)
Drug Delivery (83)
Drug Development (52693)
Employer Resources (79)
FDA (8240)
Job Trends (7988)
News (197904)
Policy (18460)
Tag
Academia (773)
Africa (423)
Alliances (30500)
Alzheimer's disease (556)
Antibody-drug conjugate (ADC) (38)
Approvals (8212)
Arizona (44)
Artificial intelligence (50)
Asia (33084)
Australia (4306)
Bankruptcy (172)
Best Places to Work (5544)
Biosimilars (57)
Biotechnology (57)
C2C Services and Suppliers (18195)
California (795)
Canada (550)
Cancer (202)
Career advice (699)
Cell therapy (37)
China (82)
Clinical research (42692)
Collaboration (71)
COVID-19 (1128)
Cystic fibrosis (42)
Data (107)
Diabetes (48)
Diagnostics (2052)
Drug pricing (73)
Earnings (40609)
Employer resources (71)
Europe (54511)
Events (49860)
Executive appointments (76)
FDA (8334)
Florida (99)
Funding (49)
Gene therapy (53)
GLP-1 (417)
Government (1869)
Healthcare (6350)
Hotbed/Location (230480)
Illinois (92)
Indiana (72)
Infectious disease (1144)
Inflammatory bowel disease (60)
Interviews (113)
IPO (7942)
IRA (31)
Job creations (2494)
Job search strategy (648)
Kansas (57)
Layoffs (241)
Legal (4377)
Lung cancer (48)
Manufacturing (60)
Maryland (146)
Massachusetts (703)
Medical device (2826)
Medtech (2828)
Mergers & acquisitions (12215)
Metabolic disorders (202)
Minnesota (75)
Neuroscience (639)
New Jersey (314)
New York (257)
NextGen Class of 2024 (2437)
Non-profit (929)
North Carolina (299)
Northern California (374)
Obesity (131)
Ohio (46)
Opinion (164)
Patents (52)
Pennsylvania (230)
People (34139)
Pharmaceutical (62)
Phase I (13232)
Phase II (18166)
Phase III (14502)
Pipeline (69)
Podcasts (47)
Policy (50)
Postmarket research (1646)
Preclinical (4713)
Press Release (31)
Rare diseases (78)
Real estate (3390)
Regulatory (12708)
Research institute (844)
Resumes & cover letters (138)
South America (645)
Southern California (327)
Startups (2190)
Texas (88)
The Weekly (31)
United States (3603)
Vaccines (166)
Washington State (93)
Weight loss (131)
Date
Last 7 days (299)
Last 30 days (1048)
Last 365 days (19929)
2024 (13378)
2023 (21036)
2022 (28343)
2021 (29274)
2020 (27271)
2019 (21480)
2018 (16669)
2017 (18571)
2016 (17509)
2015 (20333)
2014 (16098)
2013 (13765)
2012 (14775)
2011 (15091)
2010 (13836)
351,168 Results for "intec pharma ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
Essential Pharma announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.
April 9, 2024
·
5 min read
Pharm Country
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
UroGen Pharma Ltd. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants.
June 17, 2024
·
4 min read
Business
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
UroGen Pharma Ltd. today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team.
June 3, 2024
·
11 min read
Deals
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 7, 2024
UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) and an option (“Option”) to 15 new employees in connection with their employment with UroGen.
June 7, 2024
·
2 min read
Pharm Country
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
UroGen Pharma Ltd. today shared additional details about the upcoming ENVISION virtual data event on Thursday, June 13, 2024, at 11:00 a.m. Eastern Time.
June 6, 2024
·
4 min read
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
Nxera Pharma Co. Ltd, announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera.
June 26, 2024
·
3 min read
Deals
Taro Shareholders Approve Merger with Sun Pharma
Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024.
May 23, 2024
·
4 min read
Deals
Sun Pharma Completes Taro Merger
Sun Pharmaceutical Industries Limited today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) with its subsidiary.
June 24, 2024
·
1 min read
Pharm Country
UroGen Pharma to Participate at Upcoming May 2024 Investor Conferences
UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, announced that it will present at the following investor conferences in May.
May 7, 2024
·
1 min read
Press Releases
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
August 13, 2024
·
6 min read
1 of 35,117
Next
